Another record-breaking quarter for Mowi
(Bergen, 8 November 2023) Mowi recorded record-high operational revenue of 1.36 billion euros in the third quarter, compared with 1.26 billion euros in the corresponding quarter of 2022. Operational profit was 203 million euros in the quarter.
The third quarter was another record-breaking quarter for Mowi on strong operational execution. Quarterly revenues were all-time high at EUR 1.36 billion driven by record-high volumes across the group and seasonally favourable salmon prices on solid demand.
“Record-high volumes and favourable salmon prices, coupled with outstanding operational performance from my 11,500 colleagues worldwide, have culminated in another record-setting quarter for Mowi,” Mowi CEO Ivan Vindheim said.
All-time high volumes
Mowi harvested an all-time high 135 000 tonnes of salmon in the quarter. Full-year harvest volume guidance for 2023 is maintained at a record-high 484 000 tonnes. Guidance for 2024 of 500 000 tonnes marks a new all-time high and a milestone achievement for Mowi. As recently as 2018 harvest volumes were 375 000 tonnes, hence the group has grown its farming volumes by 125 000 tonnes in the period, mostly organically. Mowi's annual growth of 4.9% in the period is surpassing that of the industry of 3.2%.
“Volume growth across the value chain is one of Mowi’s strategic pillars. Growth within Mowi Farming has been impressive in recent years where crossing 500 000 tonnes in farming volumes particularly stands out,” Vindheim said.
In Mowi Farming Norway, Mowi’s most important farming entity, volume guidance for 2023 has been increased to a record-high 295 000 tonnes from 290 000 tonnes, following good seawater growth and operational performance. Volume guidance for 2024 has been set to 305 000 tonnes and crosses the 300 000 tonnes mark for the first time in Mowi's 60-year history.
“Crossing the 300 000 tonnes mark in Norway is a milestone for the company and is cementing Mowi Norway’s strong license utilisation and production efficiency. I am deeply impressed with our Norwegian organisation that continues to deliver growth and results,” Vindheim said.
Strong quarter from Consumer Products and Feed
Consumer Products delivered another strong quarter operationally and financially, with seasonal record-high volumes and operational results.
“The strong results were driven by first-rate operational performance, increased volumes and continued good demand for salmon. Despite a challenging economic environment with generally higher cost of living, demand for salmon remained robust,” Vindheim said.
Earnings in the Feed segment were seasonally record-high on strong volumes and solid operational performance. Volumes from the Norwegian plant were record-high on the back of continued strong growth in sea and increased feed requirements in Mowi Farming Norway.
The world’s most sustainable
Mowi was yesterday named the world's most sustainable producer of animal proteins by Coller FAIRR. This is the fifth consecutive year the company has topped the prestigious list that ranks the 60 largest publicly traded protein producers on a range of sustainability parameters.
“Sustainability is an important part of Mowi's DNA and is at the core of everything we do. This award once again shows that Mowi is at the forefront of sustainable food production,” Vindheim said.
Mowi’s Board has decided to pay a quarterly dividend of NOK 1.50 per share.
For further information, please contact:
Kristian Ellingsen, CFO, +47 905 14 275
Kim Galtung Døsvig, IR Officer & Head of Treasury, +47 908 76 339
Ola Helge Hjetland, Group Communications Director, +47 970 67 932
About Mowi ASA
Mowi is one of the world's leading seafood companies and the largest producer of farm-raised Atlantic salmon in the world, with an estimated harvest for 2024 of 500 000 tonnes from seven farming countries including Norway, Scotland, Ireland, Faroes, Iceland, Canada and Chile.
Mowi is a fully integrated global seafood company, bringing salmon and other seafood of supreme quality to consumers around the world, partly under its own MOWI brand. Mowi is ranked as the most sustainable listed animal protein producer in the world by Coller FAIRR.
With headquarters in Bergen, Norway, Mowi employs 11 500 people in 25 countries worldwide, and is listed on the Oslo Stock Exchange. Turnover was EUR 4.9 billion in 2022.
For more information, please visit www.mowi.com.
Forward looking statements
This release may be deemed to include forward-looking statements, such as statements that relate to Mowi's goals and strategies, salmon prices, ability to increase or vary harvest volume, production capacity, trends in the seafood industry, restructuring initiatives, exchange rate and interest rate fluctuations, expected research and development expenditures, business prospects and positioning with respect to market, demographic and pricing trends, strategic initiatives, and the effects of any extraordinary events and various other matters (including developments with respect to laws, regulations and governmental policies regulating the industry and changes in accounting policies, standards and interpretations) on Mowi's business and results. Forward-looking statements are typically identified by words or phrases, such as "believe," "expect," "anticipate," "intend," "estimate," "may increase," "may fluctuate," "plan," "goal," "target," "strategy," and similar expressions or future or conditional verbs such as "may," "will," "should," "would," and "could." Forward-looking statements are Mowi's current estimates or expectations of future events or future results. Actual results could differ materially from those indicated by these statements because the realization of those results is subject to many risks and uncertainties. Mowi ASA's Annual Report contains additional information about factors that could affect actual results, including: changes to the price of salmon including the value of our biological assets; hedging risks; risks related to fish feed; economic and market risks; environmental risks; operational risks; risks related to escapes, disease and sea lice; product risks; risks related to our acquisitions; financing risks; regulation risks including relating to food safety, the aquaculture industry, processing, competition, anti-trust and anti-corruption; trade restriction risks; litigation risks; tax and accounting risks; strategic and competitive risks; and reputation risks. All forward-looking statements included in this release are based on information available at the time of the release, and Mowi assumes no obligation to update any forward-looking statement.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Scatec at COP28: Accelerating renewable energy transition from Egypt to South Africa2.12.2023 14:01:22 CET | Press release
Dubai, 2 December 2023: This week, Scatec ASA, a leading renewable energy company, is actively engaging in the UN Climate Change Conference in Dubai (COP28). Our focus is to underscore renewable energy as an unequivocal solution to climate change and emphasise the critical need for increased green energy investments in emerging markets. COP28 serves as a pivotal platform for global stakeholders to reinforce commitments aimed at averting catastrophic consequences of climate change. Scatec aligns with climate experts in stressing the urgency of the situation and the imperative to continue advancing towards the objectives outlined in the Paris Agreement. There's no time to waste, and collective progress is crucial for safeguarding our planet's future. “We are at COP28 to highlight the key role renewable energy must play in our energy future, "At COP28, our focus is on underscoring the crucial role renewable energy must assume in shaping our energy future, particularly in emerging markets,
Unplugged Performance Introduces UP INVINCIBLE®: A Game-Changer for Tesla Cybertruck Enthusiasts2.12.2023 05:06:20 CET | Press release
HAWTHORNE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Unplugged Performance, the industry leader in performance upgrades for Tesla vehicles, debuts a new chapter in Tesla tuning with the arrival of their UP INVINCIBLE® product line. UP INVINCIBLE® is tailored exclusively for Tesla Cybertruck owners who want to push the limits of on-road and off-road performance. The unveiling took place at Unplugged Performance’s celebratory afterparty for Tesla's highly anticipated Cybertruck delivery event on November 30th. Hosted at the company's headquarters in Hawthorne, California, neighboring Tesla Design Studio, SpaceX, and Starlink, the event drew a capacity crowd, reflecting the immense enthusiasm for this innovative product range. UP INVINCIBLE® represents a concerted effort to harness and amplify the rugged DNA of the Cybertruck, making it even more robust and capable in a variety of challenging environments. During the event, Ben Schaffer, CEO of Unplugged Performance, presented an extensiv
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA2.12.2023 04:39:35 CET | Press release
SHANGHAI, China, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (TGA) has accepted the New Chemical Entity (NCE) application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC. This NCE application was submitted through Project Orbis, an initiative of
Terra Balcanica Announces Private Placement Financing1.12.2023 23:00:00 CET | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA) announces the intent to complete a non-brokered, private placement (“Private Placement”) for gross proceeds of up to $150,000 through the issuance of up to 3,750,000 common shares (“Common Shares”) at a purchase price of $0.04 per share. The Common Shares will be offered by way of prospectus exemptions in Canada and the Common Shares sold in the Private Placement will be subject to a hold period of four months plus one day. The Closing Date is expected to occur on or about December 11th, 2023, subject to regulatory approvals, including the approval by the CSE and certain other customary conditions including, but not limited to, execution of subscription agreements between the Company and the subscribers. The Private Placement will be utilized for opportuniti
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu